drugset / Trial / NCT05184192

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

NCT05184192 ↗

Phase 2 Completed 68 enrolled Washington University School of Medicine
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.

Timeline

Start
2022-01-10
Primary completion
2023-08-29
Completion
2023-08-29

Outcome

Missed primary endpoint

paper percent difference, 1.7%; 95% CI, -31.6% to 28.2% PMID 37733356 ↗

paper gabapentin was not associated with statistically significant or clinically meaningful benefit over placebo and likely is not an efficacious therapy for COVID-19-induced OD. PMID 37733356 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Unknown — Oral